efficacy of oral semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes A Review of Oral Semaglutide

TRH, thyrotropin-releasing hormone

New dual peroxisome proliferator activated receptor agonistSaroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

The short answer is that both medications can produce significant weight loss, but retatrutide appears to lead to greater average weight reduction in clinical studies because it targets three hormone receptors involved in metabolism rather than one

Retatrutide has a half-life of approximately 6 days, according to the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023)

Their bodies metabolize and eliminate the medication more quickly

You have a BMI of 27+ with weight-related conditions If youre dealing with high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea, you may qualify even at a lower BMI